相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Review of the Treatment of Mycosis Fungoides and Sézary Syndrome: A Stage-Based Approach
Steven M. Horwitz et al.
Journal of the National Comprehensive Cancer Network (2017)
Romidepsin and interferon gamma: A novel combination for refractory cutaneous T-cell lymphoma
Sara Samimi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin
Youn H. Kim et al.
LEUKEMIA & LYMPHOMA (2013)
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma
Steven M. Horwitz et al.
BLOOD (2012)
Romidepsin for Cutaneous T-cell Lymphoma
H. Miles Prince et al.
CLINICAL CANCER RESEARCH (2012)
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Richard L. Piekarz et al.
BLOOD (2011)
Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia
Mark J. Bishton et al.
BLOOD (2011)
Phase 2 Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma
Ruben Niesvizky et al.
CANCER (2011)
Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
Susan E. Bates et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
Michael Dickinson et al.
INVESTIGATIONAL NEW DRUGS (2010)
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Sean J. Whittaker et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Chemical phylogenetics of histone deacetylases
James E. Bradner et al.
NATURE CHEMICAL BIOLOGY (2010)
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
Omar Khan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
How I treat mycosis fungoides and Sezary syndrome
H. Miles Prince et al.
BLOOD (2009)
A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer
Pamela N. Munster et al.
CLINICAL CANCER RESEARCH (2009)
Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Sukyung Woo et al.
CLINICAL CANCER RESEARCH (2009)
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard L. Piekarz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Primary cutaneous lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
R. Dummer et al.
ANNALS OF ONCOLOGY (2008)
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma
Valeria R. Fantin et al.
CANCER RESEARCH (2008)
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
Leigh Ellis et al.
CLINICAL CANCER RESEARCH (2008)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma
Richard L. Piekarz et al.
CLINICAL CANCER RESEARCH (2006)
EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome
Franz Trautinger et al.
EUROPEAN JOURNAL OF CANCER (2006)
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)
RW Robey et al.
CLINICAL CANCER RESEARCH (2006)
Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo
T Ito et al.
CANCER LETTERS (2005)
Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas
TJ Mitchell et al.
IMMUNOLOGY (2005)
Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells
K Fronsdal et al.
PROSTATE (2005)
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
JC Byrd et al.
BLOOD (2005)
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance
RL Piekarz et al.
BLOOD (2004)
分享论文
